Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118)

被引:65
作者
Kim, YB
Kopcho, LM
Kirby, MS
Hamann, LG
Weigelt, CA
Metzler, WJ
Marcinkeviciene, J
机构
[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Chem Enzymol, Princeton, NJ 08543 USA
[2] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Metab Dis, Princeton, NJ 08543 USA
[3] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Discovery Chem, Princeton, NJ 08543 USA
[4] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Comp Assisted Drug Design, Princeton, NJ 08543 USA
[5] Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Macromol Struct, Princeton, NJ 08543 USA
关键词
serine protease; human DPP-IV; diabetes; GLP-1; mechanism of inhibition; dipeptide cleavage; saxagliptin; covalent intermediate;
D O I
10.1016/j.abb.2005.11.010
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dipeptidyl peptidase-IV (DPP-IV) is a serine protease with a signature Asp-His-Ser motif at the active site. Our pH data suggest that Gly-Pro-pNA cleavage catalyzed by DPP-TV is facilitated by an ionization of a residue with a pK of 7.2 +/- 0. 1. By analogy to other serine proteases this pK is suggestive of His-Asp assisted Ser addition to the PI carbonyl carbon of the Substrate to form a tetrahedral intermediate. Solvent kinetic isotope effect studies yielded a (D2O)k(cat)/K-m = 2.9 +/- 0.2 and a (D2O)k(cat) = 1.7 +/- 0.2 suggesting that kinetically significant proton transfers contribute to rate limitation during acyl intermediate formation (leaving group release) and hydrolysis. A '' burst '' of product release during pre steady-state Gly-Pro-pNA cleavage indicated rate limitation in the deacylation half-reaction. Nevertheless, the amplitude of the burst exceeded the enzyme concentration significantly (similar to 15-fold), which is consistent with a branching deacylation step. All of these data allowed us to better understand DPP-TV inhibition by saxagliptin (BMS-477118). We propose a two-step inhibition mechanism wherein an initial encounter complex is followed by covalent intermediate formation. Final inhibitory complex assembly (k(on)) depends upon the ionization of an enzyme residue with a pK of 6.2 +/- 10. 1, and we assigned it to the catalytic His-Asp pair which enhances Ser nucleophilicity for covalent addition. An ionization with a pK of 7.9 +/- 0.2 likely reflects the P2 terminal amine of the inhibitor hydrogen bonding to Glu205/Glu2O6 in the enzyme active site. The formation of the covalent enzyme-inhibitor complex was reversible and dissociated with a k(off) of (5.5 +/- 0.4.) x 10(-5) s(-1), thus yielding a K-i* (as k(off)/k(on)) of 0.35 nM, which is in good agreement with the value of 0.6 nM obtained from steady-state inhibition Studies. Proton NMR spectra of DPP-TV showed a downfield resonance at 16.1 ppm. Two additional peaks in the H-1 NMR spectra at 17.4 and 14.1 ppm were observed upon mixing the enzyme with saxagliptin. Fractionation factors (phi) of 0.6 and 0.5 for the 17.4 and 14.1 ppm peaks, respectively, are suggestive of short strong hydrogen bonds in the enzyme-inhibitor complex. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:9 / 18
页数:10
相关论文
共 42 条
[1]   Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation [J].
Aertgeerts, K ;
Ye, S ;
Tennant, MG ;
Kraus, ML ;
Rogers, J ;
Sang, BC ;
Skene, RJ ;
Webb, DR ;
Prasad, GS .
PROTEIN SCIENCE, 2004, 13 (02) :412-421
[2]   Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year [J].
Ahrén, B ;
Pacini, G ;
Foley, JE ;
Schweizer, A .
DIABETES CARE, 2005, 28 (08) :1936-1940
[3]   Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes [J].
Ahrén, B ;
Gomis, R ;
Standl, E ;
Mills, D ;
Schweizer, A .
DIABETES CARE, 2004, 27 (12) :2874-2880
[4]   Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes [J].
Ahrén, B ;
Simonsson, E ;
Larsson, H ;
Landin-Olsson, M ;
Torgeirsson, H ;
Jansson, PA ;
Sandqvist, M ;
Båvenholm, P ;
Efendic, S ;
Eriksson, JW ;
Dickinson, S ;
Holmes, D .
DIABETES CARE, 2002, 25 (05) :869-875
[5]   Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes [J].
Augeri, DJ ;
Robl, JA ;
Betebenner, DA ;
Magnin, DR ;
Khanna, A ;
Robertson, JG ;
Wang, AY ;
Simpkins, LM ;
Taunk, P ;
Huang, Q ;
Han, SP ;
Abboa-Offei, B ;
Cap, M ;
Xin, L ;
Tao, L ;
Tozzo, E ;
Welzel, GE ;
Egan, DM ;
Marcinkeviciene, J ;
Chang, SY ;
Biller, SA ;
Kirby, MS ;
Parker, RA ;
Hamann, LG .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (15) :5025-5037
[7]   CORRELATION OF PH (PD) DEPENDENCE + STEPWISE MECHANISM OF ALPHA-CHYMOTRYPSIN-CATALYZED REACTIONS [J].
BENDER, ML ;
CLEMENT, GE ;
HECK, HD ;
KEZDY, FJ .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1964, 86 (18) :3680-&
[8]   Tyrosine 547 constitutes an essential part of the catalytic mechanism of dipeptidyl peptidase IV [J].
Bjelke, JR ;
Christensen, J ;
Branner, S ;
Wagtmann, N ;
Olsen, C ;
Kanstrup, AB ;
Rasmussen, HB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (33) :34691-34697
[9]   DIPEPTIDE PHOSPHONATES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV [J].
BODUSZEK, B ;
OLEKSYSZYN, J ;
KAM, CM ;
SELZLER, J ;
SMITH, RE ;
POWERS, JC .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (23) :3969-3976
[10]   A new concept for the mechanism of action of chymotrypsin: The role of the low-barrier hydrogen bond [J].
Cassidy, CS ;
Lin, J ;
Frey, PA .
BIOCHEMISTRY, 1997, 36 (15) :4576-4584